China’s Pharma Manufacturing Monopoly

China is seeking to disrupt, dominate, and displace America’s pharmaceutical and other medical-industry manufacturing companies, and in doing so, limit U. S. ability to produce its own medicines, including antibiotics such as penicillin and even generic aspirin.  In the age of sporadic pandemics, this represents an unacceptable strategic vulnerability.  How did we get here?  What are the implications?  And what can be done about it?  We’ll show you.

This content is for TRENDS SUBSCRIPTION members only.
Login Join Now